Palisade Bio Takes Significant Step in Ulcerative Colitis Treatment
Palisade Bio, Inc. (Nasdaq: PALI) has embarked on an exciting journey as it commences dosing in the first cohort of patients with ulcerative colitis (UC) within its ongoing Phase 1a/b study focusing on PALI-2108. This clinical-stage biopharmaceutical company is dedicated to advancing innovative therapeutics aimed at helping those dealing with autoimmune, inflammatory, and fibrotic diseases.
So far, the preliminary data from the study is encouraging. The results from all five single ascending dose (SAD) cohorts, along with the three completed multiple ascending dose (MAD) cohorts, indicate that PALI-2108 is both safe and well-tolerated. Remarkably, there have been no serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) that connect to laboratory values or electrocardiograms (EKGs), underscoring the promise of this investigational therapy.
Positive Safety Profile and Evolving Study Insights
The initiation of dosing in the final cohort marks a milestone in the study. In addition to the completion of the SAD cohorts, Palisade has also successfully wrapped up the first three MAD cohorts. These results indicate that the observed TEAEs were predominantly mild, with only one withdrawal recorded at the highest MAD dosage. Notably, two of the MAD cohorts were finished within the expected therapeutic dose bracket, again highlighting the absence of SAEs or TEAEs intertwined with lab results or EKGs.
Expert Insight on Progress
Dr. Mitch Jones, the Chief Medical Officer of Palisade, expressed his enthusiasm about transitioning from healthy volunteers to dosing patients with UC. The preliminary outcomes from both the SAD and MAD cohorts have aligned with management’s expectations. Dr. Jones emphasized the importance of these results, saying, "We look forward to additional evaluations and are on track to disclose topline data in the near future," signaling strong anticipation of findings in the coming months.
Understanding PALI-2108 and Its Impact
The key goal of this Phase 1a/b study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PALI-2108. This new chemical entity has not been administered to humans in prior studies, making this research particularly critical. The investigation of biomarkers including serum high sensitivity C-reactive protein (hsCRP) and fecal calprotectin (CalPro) will add further depth to the understanding of how PALI-2108 performs.
Key Biomarkers Under Investigation
In addition to the biomarkers mentioned, the study will evaluate colonic tissue histology assessments. This analysis will consider drug and metabolite levels, as well as PDE4 expression and cyclic adenosine monophosphate (cAMP) levels. These factors are integral to grasping the drug’s mechanism and overall efficacy in treating UC.
Looking Ahead: Exciting Future for Palisade Bio
Palisade Bio continues to set a standard in the treatment landscape for individuals living with UC and other related conditions. The positive momentum gained from the study's results might pave the way for PALI-2108 becoming a transformative treatment option for those affected by this challenging disease.
To learn more about the ongoing Phase 1a/b study, interested individuals may find additional details on the clinical trials page.
Frequently Asked Questions
What is PALI-2108?
PALI-2108 is an investigational drug developed by Palisade Bio aimed at treating ulcerative colitis.
What are the main goals of the Phase 1a/b study?
The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PALI-2108 in both healthy volunteers and UC patients.
How is the dosing progress so far?
The dosing for the first cohort of UC patients has commenced, with promising preliminary data showing no serious adverse events.
What results have been seen from previous cohorts?
Previous cohorts have shown that PALI-2108 is well tolerated with no significant adverse events reported to date.
What does the future hold for Palisade Bio?
The company is on track to release topline data soon, indicating strong progress in its clinical trials and research endeavors.
